Episurf Medical achieves milestone of 150th implant

Episurf will achieve its 150th implant during the week of 28th November 2016. This milestone of Episealer knee implant surgeries demonstrates the increasing rate of adoption within the orthopaedic community for the Episurf Medical’s patient specific approach for the treatment of focal cartilage lesions.

This information was published, 2016-11-28 08:00 CET (GLOBE NEWSWIRE) —

“The Episealer concept is gaining traction and less than 6 months after case number 100, we are now reaching 150.  The orthopaedic surgical implant market is decidedly conservative and incrementally, Episurf is moving into the area of evidence-based medicine. The results to date are very encouraging and builds further optimism as they show rapid recovery along with a significant improvement in the quality of life for our patients”, said Dr Leif Ryd, Senior Medical Advisor to Episurf Medical.

“We are pleased to have reached this point so quickly after our 100th surgery”, said Rosemary Cunningham Thomas, CEO of Episurf Medical. “Surgeons are deciding for themselves in increasing numbers that the Episealer procedure provides significant improvements for their patients. The personalised approach, which starts with our Epioscopy® process to fully visualise and assess a patient’s cartilage damage, enables Episurf to tailor every implant to a patient’s specific anatomy and pathology. Our results are being borne out through solid clinical outcomes and a growing forward order book.’’


For more information, please contact:

Rosemary Cunningham Thomas, CEO, Episurf Medical

Tel: +46 (0) 70-7655892

Tel: +44 (0) 7803-753603

Email: rosemary@episurf.com


About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above.